In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.

AUTOR(ES)

Sanchez, M L

RESUMO

The in vitro activity of decaplanin (formerly M86-1410), a novel glycopeptide antimicrobial agent, was tested against 169 gram-positive bloodstream isolates from patients at the University of Iowa Hospitals and Clinics and 12 selected vancomycin-resistant strains. Enterococcus faecalis, E. faecium, Staphylococcus aureus, streptococci, bacilli, corynebacteria, and listeria were inhibited by decaplanin (MICs for 90% of the strains tested [MIC90s], 0.12 to 4 micrograms/ml). However, some rarely isolated and selected Enterococcus sp. populations had a MIC90 of 16 micrograms/ml, and S. haemolyticus strains had a MIC90 of 8 micrograms/ml. These in vitro results suggest that decaplanin may be useful against most gram-positive strains, even though some Enterococcus species and coagulase-negative staphylococci were potentially resistant (MICs, greater than or equal to 8 micrograms/ml).

Documentos Relacionados

• In vitro activity of SK&F 104662, a new glycopeptide antibiotic.
• Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.
• In vitro activity of midecamycin, a new macrolide antibiotic.
• Comparative in vitro activity of CGP 31608, a new penem antibiotic.
• In vitro antibacterial activity of KP-736, a new cephem antibiotic.